# Fibraten gekoppeld aan lager cardiovasculair risico bij chronische nierziekte — retrospectieve cohortstudie

*geplaatst 2026-11-21 · Nierziekte · Kidney international reports · doi 10.1016/j.ekir.2026.107116 · https://hartvaat.nl/2026/12/01/fibraten-gekoppeld-aan-lager-cardiovasculair-risico-bij-chronische-nierziekte-re/*

In een retrospectieve cohortstudie onder 46.904 patiënten met incidentele chronische nierziekte (CKD) werd het cardiovasculaire risico vergeleken bij het starten van fibraten, niacine of statines. Gebruik van fibraten was geassocieerd met een lager risico op MACE (HR 0,93; 95% BI 0,86-0,99) ten opzichte van statines, een effect dat voornamelijk werd gedreven door een 13% lager risico op hartfalen. Niacine toonde geen significant verschil. Deze bevindingen uit een grote nationale cohortstudie bieden extra context voor het lipidmanagement bij CKD, hoewel de retrospectieve opzet beperkingen met zich meebrengt voor directe toepassing in de dagpraktijk.

## English: Cardiovascular Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies in Patients with CKD.

In a retrospective cohort study of 46,904 patients with incident chronic kidney disease (CKD), cardiovascular outcomes were compared between those initiating fibrates, niacin, or statins. Fibrate use was associated with a modestly lower risk of major adverse cardiovascular events (MACE) compared to statins (HR 0.93; 95% CI 0.86–0.99), primarily driven by a 13% reduction in heart failure risk, while niacin showed no significant difference. These findings from a large nationwide cohort add to the evidence on triglyceride-targeting therapies in CKD, though the observational design limits definitive clinical recommendations.

## Abstract (original, from the publication)

INTRODUCTION: In patients with chronic kidney disease (CKD), atherogenic lipid profiles, characterized by hypertriglyceridemia and impaired high-density lipoprotein cholesterol (HDL-C) metabolism, contribute to adverse cardiovascular disease (CVD) outcomes. Since evidence on CVD outcomes of triglyceride-targeting lipid-lowering therapies (LLTs), such as fibrates and niacin, remains limited, kidney disease guidelines recommend further investigation. METHODS: We designed this retrospective cohort study using a target trial emulation framework and leveraged data from a nationwide cohort of 3,562,882 US Veterans to identify 46,904 patients with incident CKD initiating de novo fibrate, niacin, or statin therapy. We compared the risk of major adverse cardiovascular events (MACE; composite of acute myocardial infarction, ischemic stroke, congestive heart failure, or all-cause death) using Cox proportional hazards models adjusted for baseline covariates during follow-up of up to 10 years. RESULTS: 16,191 patients (event rate, 79.2; 95% confidence interval [CI], 78.0-80.4 per 1000 person-years) experienced MACE after a median follow-up of 3.70 years. The risk of MACE was significantly lower (hazard ratio [HR], 0.93 [95% CI, 0.86-0.99]; P = 0.03) in de novo fibrate users compared with statin users. Niacin users, however, did not have a significantly different risk of MACE (1.03 [0.95-1.12]; P = 0.42) than statin users. The result was largely attributable to the association between fibrate use and congestive heart failure (CHF)-a statistically significant 13% lower hazard (0.87 [0.78-0.96]; P = 0.005) compared with statin use. CONCLUSION: In this large nationwide cohort of patients with nonkidney replacement therapy-dependent CKD, de novo fibrate use, but not niacin use, was associated with a lower risk of MACE than de novo statin use.

Auteurs: Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert Lowell Davis, Kamyar Kalantar-Zadeh, Keiichi Sumida, Csaba P Kovesdy

---
Bron: Kidney international reports, https://doi.org/10.1016/j.ekir.2026.107116. Bijgewerkt 2026-11-15T02:10:00Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.
